ClinicalTrials.gg
CompletedNCT01118377Updated Feb 6, 2014Results posted

A Study of Capecitabine (Xeloda®) and Concomitant Radiation Therapy in Children With Newly Diagnosed Brainstem Gliomas

A Phase 2 interventional study of Capecitabine and Radiation therapy in Brainstem Glioma, sponsored by Hoffmann-La Roche. Completed at 8 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-02-06.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
3 Years to 17 Years
Sex
All
01

Study summary

This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.

Read the detailed description

The open-label phase 2 study NO21125 (NCT01118377) evaluated the progression-free survival, safety, and pharmacokinetics of capecitabine (Xeloda®) rapidly disintegrating tablets and concomitant radiation therapy in children and adolescent patients with newly diagnosed brainstem glioma. There were 2 phases to the study: A 9-week radiation phase, followed by a 2-week rest period, and a 9-week post-radiation phase. In the radiation phase, capecitabine 650 mg/m\^2 was administered orally twice daily for 9 weeks. Concomitantly, patients received radiation therapy (180 cGy fractions) 5 days a week for a total target dose of 56 Gy. During the 9-week post-radiation phase of the study, capecitabine 1250 mg/m\^2 was administered orally twice daily for 14 days followed by a 7-day rest period. This cycle of 14 days treatment followed by 7 days rest was repeated 2 additional times. The dose could be adjusted according to toxicity and body surface area.

The single-arm phase 1 study NO18517 (NCT00532948) assessed the maximum tolerated dose and dose-limiting toxicities of capecitabine (Xeloda®) administered concurrently with radiation therapy in children with newly diagnosed diffuse intrinsic brain stem gliomas and high grade gliomas. Patients in the phase 1 study NO18517 who were diagnosed with intrinsic brainstem glioma and who were treated at the established maximum tolerated dose of capecitabine 650 mg/m\^2/dose twice a day were included in the analyses of the phase 2 study NO21125.

The efficacy and safety results of study NO21125 are reported below.

02

Conditions studied

  • Brainstem Glioma
03

In context

Lead sponsor

Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.

Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric and adolescent patients ≥ 3 to \< 18 years of age.
  • Patients must have a newly diagnosed non-disseminated intrinsic infiltrating brainstem glioma.
  • Performance Scale (if > 16 years of age) or Lansky Performance Score (if ≤ 16 years of age) ≥ 50% assessed within 2 weeks prior to registration to study.
  • Patients must not have received any prior chemotherapy or bone marrow transplant for the treatment of brainstem glioma. Prior dexamethasone and/or surgery are allowed.
  • Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Patients receiving any other anticancer or experimental drug therapy.
  • Patients with uncontrolled infection.
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Capecitabine + radiation therapy

    Participants received 9 weeks of capecitabine 650 mg/m\^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m\^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.

    Drug: Capecitabine · Radiation: Radiation therapy

Interventions

  • Capecitabine was supplied as film-coated tablets.

    Also known as: Xeloda

  • RadiationRadiation therapy

    Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.

06

What researchers measure

Primary outcomes

  1. Progression-free Survival

    Progression-free survival was defined as the time from the initiation of treatment to the earliest date of failure (disease progression, death from any cause, or a second malignancy) or to the last assessment date for patients who did not fail. Disease progression was defined as progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (eg, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, weaning of steroids, radiation necrosis, etc); or a greater than 25% increase in the bi-dimensional measurement of the tumor, as compared with the previous scan; or the appearance of a new lesion; or an increase in the doses of dexamethasone required to maintain stable neurologic status or imaging.

    Time frame: Baseline to the end of the study (up to 20 weeks)

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the initiation of therapy to the date of death from any cause or to the date the patient was last known to be alive for surviving patients.

    Time frame: Baseline to the end of the study (up to 20 weeks)

  2. Percentage of Participants With a Tumor Response

    Tumor response was defined as either a complete response or a partial response prior to failure (disease progression, death from any cause, or a second malignancy). A complete response was defined as the complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. A partial response was defined as a greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks.

    Time frame: Baseline to the end of the study (up to 20 weeks)

07

Results

Posted Dec 3, 2013

Participant flow

Participant flow — Overall Study
MilestoneCapecitabine + Radiation Therapy
Started45
Completed3
Not completed42
Withdrew: Did not receive study medication1
Withdrew: Death38
Withdrew: Failure to return3

Outcome measures

PrimaryProgression-free Survival

Progression-free survival was defined as the time from the initiation of treatment to the earliest date of failure (disease progression, death from any cause, or a second malignancy) or to the last assessment date for patients who did not fail. Disease progression was defined as progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (eg, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, weaning of steroids, radiation necrosis, etc); or a greater than 25% increase in the bi-dimensional measurement of the tumor, as compared with the previous scan; or the appearance of a new lesion; or an increase in the doses of dexamethasone required to maintain stable neurologic status or imaging.

Time frame:
Baseline to the end of the study (up to 20 weeks)
Reported as:
Median · Months
Progression-free Survival
MonthsCapecitabine + Radiation Therapy
Progression-free Survival4.9 (4.5 to 6.0)
SecondaryOverall Survival

Overall survival was defined as the time from the initiation of therapy to the date of death from any cause or to the date the patient was last known to be alive for surviving patients.

Time frame:
Baseline to the end of the study (up to 20 weeks)
Reported as:
Median · Months
Overall Survival
MonthsCapecitabine + Radiation Therapy
Overall Survival10.3 (7.7 to 12.9)
SecondaryPercentage of Participants With a Tumor Response

Tumor response was defined as either a complete response or a partial response prior to failure (disease progression, death from any cause, or a second malignancy). A complete response was defined as the complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. A partial response was defined as a greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks.

Time frame:
Baseline to the end of the study (up to 20 weeks)
Reported as:
Number · Percentage of participants
Percentage of Participants With a Tumor Response
Percentage of participantsCapecitabine + Radiation Therapy
Percentage of Participants With a Tumor Response2.3 (0.1 to 12.0)

Adverse events

Collected over Adverse events were reported from Baseline up to 30 days after the last treatment (up to 24 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine + Radiation Therapy—23/44 (52.3%)44/44 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventCapecitabine + Radiation Therapy
Neutrophil count decreasedInvestigations5/44
Central nervous system necrosisNervous system disorders3/44
HydrocephalusNervous system disorders3/44
ConvulsionNervous system disorders2/44
Neurological symptomNervous system disorders2/44
Disease progressionGeneral disorders2/44
PyrexiaGeneral disorders2/44
White blood cell count decreasedInvestigations2/44
DiarrhoeaGastrointestinal disorders2/44
DysphagiaGastrointestinal disorders2/44
Most frequent other events
Showing 10 of 73
Most frequent other events
EventCapecitabine + Radiation Therapy
VomitingGastrointestinal disorders35/44
Alanine aminotransferase increasedInvestigations33/44
Lymphocyte count decreasedInvestigations32/44
White blood cell count decreasedInvestigations27/44
Platelet count decreasedInvestigations25/44
HypoalbuminaemiaMetabolism and nutrition disorders21/44
HeadacheNervous system disorders20/44
HypokalaemiaMetabolism and nutrition disorders18/44
FatigueGeneral disorders18/44
HypocalcaemiaMetabolism and nutrition disorders17/44

Baseline characteristics

Intent-to-treat population: All enrolled participants who received at least 1 dose of capecitabine. One of the 45 participants did not receive treatment and was not included in the intent-to-treat population (34 participants from study NO21125 and 10 participants from study NO18517).

Age, Continuous
Age, Continuous(years)Capecitabine + Radiation Therapy
Mean7.5 ± 3.69
Sex: Female, Male
Sex: Female, Male(Participants)Capecitabine + Radiation Therapy
Female22
Male22
08

Study locations

8 sites
  • San Francisco, California 94143-0780, United States
  • Washington, District of Columbia 20010, United States
  • Chicago, Illinois 60614, United States
  • Durham, North Carolina 27710, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Pittsburgh, Pennsylvania 15261, United States
  • Memphis, Tennessee 38015, United States
  • Houston, Texas 77030, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2007, a primary completion of Jan 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2010
First posted
May 6, 2010
Start
May 2007
Primary completionActual
Jan 2013
CompletionActual
Apr 2013
Results first posted
Dec 3, 2013
Last update
Feb 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01118377
Lead sponsor
Hoffmann-La Roche
Collaborators
Pediatric Brain Tumor Consortium
Responsible party
Sponsor
First posted
May 6, 2010
Start date
May 2007
Primary completion
Jan 2013
Completion
Apr 2013
Results posted
Dec 3, 2013
Last update
Feb 6, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Capecitabine

Start the discussion